Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q3 2019 Earnings Conference Call - Final Transcript
Nov 11, 2019 • 08:00 am ET
Greetings. Welcome to the Pieris Pharmaceuticals Third Quarter 2019 Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
At this time, I'll turn the conference over to Tom Bures, Vice President of Finance. Sir, you may begin.
Good morning, everyone. And thank you for joining us for our third quarter 2019 conference call and corporate update. You can access the press release issued this morning on the Investor Relations page of our website at www.pieris.com.
Before we begin, I would like to caution that comments made during this conference call may contain forward-looking statements involving risks and uncertainties regarding the operations and future results of operations of Pieris, including statements related to the timing and progress of our clinical trials and preclinical programs, our partnerships and our financial position and actual results or events that may differ materially from those expressed or implied by such forward-looking statements.
Factors that might cause such differences are described in our filings with the SEC, including our annual, quarterly and current reports. The information being presented is only accurate as of today, and Pieris undertakes no obligation to update any statements to reflect future events or circumstances.
I'll now turn the call over to Steve Yoder, our President and CEO.
Thank you, Tom, and thank you to everyone for joining us today for our 2019 third quarter earnings call. I would like to start my comments by introducing new voices on the call today. For those of you who know my voice, it sounds a little different today. I think that's merely reflective of all the outreach we've been doing after our very positive data at SITC for PRS-343 and more on that in a few moments.
You briefly heard from Tom Bures, our VP of Finance, who has been serving in that capacity since joining Pieris roughly two years ago. After I share more recent pipeline progress and plans for the remainder of the year, you will hear once again from Tom who will walk you through our third quarter financials, which we believe continue to reflect an efficient deployment of capital at Pieris.
Afterwards, we'll move to a Q&A session, providing an opportunity to hear from Dr. Ingmar Bruns, who heads clinical development at Pieris, as well as Dr. Shane Olwill, who oversees translational science at the company. The recent biomarker-driven positive clinical readouts from both PRS-060 and PRS-343 are clear examples of the continued productivity of R&D efforts led by Ingmar and Shane. At our R&D day in New York City on November 19, which will be webcast. We also intend to provide more details on programs as well as how these recent clinical data inform our thinking on investing in additional therapeutic programs.
Now moving to a brief recap of our technology platform and R&D strategy, I would like to remind everyone that Pieris has developed a proprietary class of